文献速递主动脉疾病

STABLE II 研究五年结果:复合装置腔内治疗复杂性急性B型主动脉夹层

Five-year results of the STABLE II study for the endovascular treatment of complicated, acute type B aortic dissection with a composite device design.
PubMed 文献 · J Vasc Surg · 2022-07-07

STABLE II 为前瞻性多中心研究,纳入73例急性B型主动脉夹层合并灌注不良或破裂患者,使用Zenith夹层腔内系统(近端覆膜支架+远端裸支架复合装置或仅近端支架)。5年随访显示夹层相关死亡率低(1至5年无夹层相关死亡均为97.1%±2.1%),复合装置组假腔血栓形成或消除率高于无裸支架组(90.5% vs 57.1%),但所有患者需持续监测远端主动脉扩张。

要点

  • 5年无全因死亡为68.9%±7.3%,1年无全因死亡为80.3%±4.7%。
  • 5年无夹层相关死亡自1年至5年维持97.1%±2.1%。
  • 5年支架移植物区域内假腔完全血栓形成或消除率复合装置组90.5% vs 无裸支架组57.1%。

核心结论

  • 5年结果提示Zenith夹层腔内系统治疗急性复杂性B型主动脉夹层夹层相关死亡率低。
  • 数据提示复合装置的使用对假腔血栓形成有积极影响。
  • 所有患者均需持续监测远端主动脉扩张。

研究设计与样本

  • STABLE II 为前瞻性、多中心研究,使用Zenith夹层腔内系统(William Cook Europe)。
  • 2012年8月至2015年1月在美国和日本的研究中心入组患者,5年随访于2020年1月完成。
  • 共纳入73例急性B型主动脉夹层患者,平均年龄60.7±10.9岁,65.8%为男性。

主要发现

  • 患者夹层合并灌注不良72.6%、破裂21.9%、两者兼有5.5%。
  • 79.5%患者接受复合装置,20.5%仅接受近端覆膜支架(无远端裸支架)。
  • 复合装置组夹层范围408.9±121.3 mm,无裸支架组315.9±100.1 mm。
  • 平均随访1209.4±754.6天;1年无全因死亡80.3%±4.7%,5年68.9%±7.3%。
  • 5年支架移植物区域内假腔完全血栓形成或消除率复合装置组90.5% vs 无裸支架组57.1%。

关键数值与推荐

  • 1年无全因死亡为80.3%±4.7%,5年为68.9%±7.3%。
  • 1年至5年无夹层相关死亡维持97.1%±2.1%。
  • 支架移植物区域内假腔完全血栓形成或消除率随时间增加:5年全患者82.1% vs 术后首次CT 55.7%。
  • 5年时支架移植物区域内最大主动脉横径减小者20.7%、增大者17.2%、无变化者62.1%。
  • 5年无任何二次干预为70.7%±7.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide the 5-year outcomes of the use of a composite device (proximal covered stent graft + distal bare stent) for endovascular repair of patients with acute, type B aortic dissection complicated by aortic rupture and/or malperfusion. METHODS: Study of Thoracic Aortic Type B Dissection Using Endoluminal Repair (STABLE) II was a prospective, multicenter study of the Zenith Dissection Endovascular System (William Cook Europe). Patients were enrolled between August 2012 and January 2015 at sites in the United States and Japan. Five-year follow-up was completed by January 2020. RESULTS: In total, 73 patients (mean age: 60.7 ± 10.9 years; 65.8% male) with acute type B dissection complicated by malperfusion (72.6%), rupture (21.9%), or both (5.5%) were enrolled. Patients were treated with either a composite device (79.5%) or the proximal stent graft alone (no distal bare stent, 20.5%). Dissections were more extensive in patients who received the composite device (408.9 ± 121.3 mm) than in patients who did not receive a bare stent (315.9 ± 100.1 mm). The mean follow-up was 1209.4 ± 754.6 days. Freedom from all-cause mortality was 80.3% ± 4.7% at 1 year and 68.9% ± 7.3% at 5 years. Freedom from dissection-related mortality remained at 97.1% ± 2.1% from 1-year through 5-year follow-up. Within the stent-graft region, the rate of either complete thrombosis or elimination of the false lumen increased over time (82.1% of all patients at 5 years vs 55.7% at first postprocedure computed tomography), with a higher rate at 5 years in patients who received the composite device (90.5%) compared with patients without the bare stent (57.1%). Throughout the follow-up, overall true lumen diameter increased within the stent-graft region, and overall false lumen diameter decreased. At 5 years, 20.7% of patients experienced a decrease in maximum transaortic diameter within the stent-graft region, 17.2% experienced an increase, and 62.1% experienced no change. Distal to the treated segment (but within the dissected aorta), 23.1% of patients experience no change in transaortic diameter at 5 years; a bare stent was deployed in all these patients at the procedure. Five-year freedom from all secondary intervention was 70.7% ± 7.2%. CONCLUSIONS: These 5-year outcomes indicate a low rate of dissection-related mortality for the Zenith Dissection Endovascular System in the treatment of patients with acute, complicated type B aortic dissection. Further, these data suggest a positive influence of composite device use on false lumen thrombosis. Continuous monitoring for distal aortic growth is necessary in all patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lombardi JV, Gleason TG, Panneton JM, et al. Five-year results of the STABLE II study for the endovascular treatment of complicated, acute type B aortic dissection with a composite device design. J Vasc Surg. 2022. PMID: 35809819. doi:10.1016/j.jvs.2022.06.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。